Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4834771 | 0.80 | — | — | |
| SCHEMBL20158951 | 0.77 | GNAI3 (0.32) | NCF1 | |
| SCHEMBL22147436 | 0.75 | — | — | |
| SCHEMBL14594827 | 0.75 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL14594830 | 0.75 | PIK3CD (0.40) | ALDH1A1 | |
| SCHEMBL12243856 | 0.74 | MEN1 (0.40) | NCF1ALDH1A1 | |
| SCHEMBL10316250 | 0.73 | ALDH1A1 (0.37) | NCF1ALDH1A1 | |
| SCHEMBL15223506 | 0.73 | NCF1 (0.37) | NCF1ALDH1A1 | |
| SCHEMBL10895308 | 0.73 | CES2 (0.38) | ALDH1A1 | |
| SCHEMBL801091 | 0.73 | ALDH1A1 (0.38) | NCF1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | NANJING IMMUNOPHAGE BIOMEDICAL CO., LTD. (CN) | 2023-05-25 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-05-17 | — | — | US | disclosed |
| US-8796460-B2 | Compounds for inhibiting KSP kinesin activity | Mercky Sharp & Dohme Corp. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-03-22 | — | — | US | disclosed |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-07-14 | — | — | US | disclosed |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME CORP. | 2011-06-23 | — | — | US | disclosed |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | MERCK SHARP & DOHME LLC | 2011-05-26 | — | — | US | disclosed |
| WO-2010096462-A1 | LINKED DIIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159446-A1 | Methods and Compositions for Targeting Tregs using CCR8 Inhibitors | CCR8, CCR1, CCR3 | NCF1 243/4885ALDH1A1 2716/4885 |
| US-20110150757-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF18B, KIF5B, KIF18A | NCF1 2521/4885ALDH1A1 2246/4885 |
| US-20120070370-A1 | SPIRO 1,3,4-THIADIAZOLINE DERIVATIVES AS KSP INHIBITORS | KIF2C, SKP1, KIF5B | NCF1 2471/4885ALDH1A1 1081/4885 |
| US-20110123435-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | NCF1 1802/4885ALDH1A1 2214/4885 |
| US-20180134690-A1 | INDAZOLES AND USE THEREOF | TRPV3, TRPA1, TRPV1 | NCF1 2992/4885ALDH1A1 710/4885 |
| US-20110171172-A1 | COMPOUNDS FOR INHIBITING KSP KINESIN ACTIVITY | KIF5B, KIF2C, KIFC1 | NCF1 2060/4885ALDH1A1 1933/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.